ArticleEULAR rheumatology open2025

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

Line Uhrenholt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.